دورة المؤشرنت للتحليل الفني
50 دينار كويتي
متابعة stem
- بادئ الموضوع jamal
- تاريخ البدء
السهم الامريكي
عضو نشط
احسنت 3ز42
$$ الطمـــوح $$
عضو نشط
- التسجيل
- 12 أغسطس 2004
- المشاركات
- 476
وش هالطلوع المفاجىء أخوي جمال؟؟
السهم الامريكي
عضو نشط
3.75 $
3.75 $
3.75 $
لا اعلم ان كان خبر لا اتابع الاخبار .. ولكن هناك mini pop و pop على الديلى
والويكلى والمونتلى جيد .. يفترض الدخول عند نقطة ارتكاز السهم وهي 2.76
ولكن حال السوق لا يطمأن قلب .. ولكن يجب المتابعه هذا الاسبوع
لعله الوصول الى 4.40 .. وشكرا وفقكم الله
والويكلى والمونتلى جيد .. يفترض الدخول عند نقطة ارتكاز السهم وهي 2.76
ولكن حال السوق لا يطمأن قلب .. ولكن يجب المتابعه هذا الاسبوع
لعله الوصول الى 4.40 .. وشكرا وفقكم الله
السهم الامريكي
عضو نشط
4 دولار
ما شاء الله
ما شاء الله
السهم الامريكي
عضو نشط
4.22 $
4.22 $
4.22 $
السهم الامريكي
عضو نشط
4.66 $
4.66 $
4.66 $
بس الحمدلله طلعنا منا غانمين . 
love life
عضو نشط
- التسجيل
- 16 يوليو 2004
- المشاركات
- 271
StemCells, Inc. (Nasdaq:STEM) announced today that it has entered into definitive agreements with institutional investors with respect to the registered direct placement of 7,500,000 shares of its common stock at a purchase price of $3.00 per share, for gross proceeds of approximately $22,500,000. C.E. Unterberg, Towbin, LLC and Shoreline Pacific, LLC served as placement agents for the transaction.
SAIFY
عضو نشط
- التسجيل
- 4 أغسطس 2004
- المشاركات
- 342
اخبار و توصيه من موقع مو مني لمتابعه و شكر لاخ JAMAL
We knew it was a matter of time before stem cell stocks took off. The
biggest screamers in the sector have thus far been StemCells Inc (STEM) up 51.58% and Aastrom Biosciences (ASTM) gaining 25.22%. These tremendous moves to the upside occurred on Monday alone. Both of these companies should be familiar to readers as they were all included in our Stem Cell Research Basket in July of 2003.
In retrospect, STEM and ASTM were no brainers since both are based in California. In less than two weeks the voters of the Golden State will decide if the California Stem Cell Research and Cures Initiative aka Proposition 71 passes. The statewide ballot would authorize an average of $295 million per year over ten years in tax-free state bonds to support stem cell research at California's universities, medical schools and research facilities.
Unfortunately, only bay area based stem cell research company Geron (GERN) was included in our Biotech Basket II edition. The stock has done pretty well having risen from $6.69 per share to close yesterday at $7.75 per share good for a quick 15.8% gain in less than a week. It's going to be fun watching these stocks trade huge volumes for the next two weeks. Fundamentally, if Prop 71 passess the impact will not be known immediately but chances are good that stem cells become the topic of coffee tables around the country again.
For more information on stem cells please visit one of our past editions Stem Cells: The Future Of Medicine.
Trying To Break Resistance Levels
Last week we issued a trading alert on Diabetic Treatment Centers of America (DBTC) with a short term target of $1.65 per share representing a potential gain of 43.47%. At the time of the alert the stock closed at $1.15 per share with 22.72 million shares outstanding bringing the market cap to $26.13 million.
DBTC made a nice move up to $1.24 per share but was unable to penetrate this major resistance level despite trading over half a million shares. This marks the third time that the wall at $1.24 was unable to be broken The stock has since pulled back to close yesterday at $1.05 per share. Considering that DBTC has had a nice run in the past month, the current retracement is healthy. Our timing could have been better but we see these levels as an opportunity.
In our opinion, the chances are good that the $1.24 price point will be challenged a fourth time. Breaking through this pivotal wall will mean new highs while a fourth failure would have us concerned.
We knew it was a matter of time before stem cell stocks took off. The
biggest screamers in the sector have thus far been StemCells Inc (STEM) up 51.58% and Aastrom Biosciences (ASTM) gaining 25.22%. These tremendous moves to the upside occurred on Monday alone. Both of these companies should be familiar to readers as they were all included in our Stem Cell Research Basket in July of 2003.
In retrospect, STEM and ASTM were no brainers since both are based in California. In less than two weeks the voters of the Golden State will decide if the California Stem Cell Research and Cures Initiative aka Proposition 71 passes. The statewide ballot would authorize an average of $295 million per year over ten years in tax-free state bonds to support stem cell research at California's universities, medical schools and research facilities.
Unfortunately, only bay area based stem cell research company Geron (GERN) was included in our Biotech Basket II edition. The stock has done pretty well having risen from $6.69 per share to close yesterday at $7.75 per share good for a quick 15.8% gain in less than a week. It's going to be fun watching these stocks trade huge volumes for the next two weeks. Fundamentally, if Prop 71 passess the impact will not be known immediately but chances are good that stem cells become the topic of coffee tables around the country again.
For more information on stem cells please visit one of our past editions Stem Cells: The Future Of Medicine.
Trying To Break Resistance Levels
Last week we issued a trading alert on Diabetic Treatment Centers of America (DBTC) with a short term target of $1.65 per share representing a potential gain of 43.47%. At the time of the alert the stock closed at $1.15 per share with 22.72 million shares outstanding bringing the market cap to $26.13 million.
DBTC made a nice move up to $1.24 per share but was unable to penetrate this major resistance level despite trading over half a million shares. This marks the third time that the wall at $1.24 was unable to be broken The stock has since pulled back to close yesterday at $1.05 per share. Considering that DBTC has had a nice run in the past month, the current retracement is healthy. Our timing could have been better but we see these levels as an opportunity.
In our opinion, the chances are good that the $1.24 price point will be challenged a fourth time. Breaking through this pivotal wall will mean new highs while a fourth failure would have us concerned.
الملفات المرفقه:
السلام عليكم .. اخى الكريم اسال الله ان تكون خرجت من هذا السهم وانت راضى النفس قبل كل شيء
اريد ان احذرك من شيء مهم نوعية هذه الاسهم وهي تحت 10 دولار مخيفه جدا
الخبر يشكل دور مهم فى ارتفاع هذه الاسهم + التداول وخبر يشكل انفجار
لو نظرت اخى الكريم فى مستوى حركته اليوميهقبل الخبر لا يتعدى 20 سنت فى ارتفاع ونزول ولكن الخبر الجيد + التداول الممتاز يجعل من حركته قويه وسريعه
نصيحتى لك لا تملك السهم اكثر من يوم واحد لكي تظمن حقك
من حيث التحليل ..اصبح السهم محصور ما بين 3.30 الديلى و4 الدولار
الديلى لا يقول به اندفاع كبير .. المقاومه الاتيه 3.61 والاقوى 3.93
والويكلى يشير الى السقوط الى 2.90
السهم ينتظر خبر جيد لكي يعاود الرتفاع مره اخرى وبقوة .. وفقك الله
اريد ان احذرك من شيء مهم نوعية هذه الاسهم وهي تحت 10 دولار مخيفه جدا
الخبر يشكل دور مهم فى ارتفاع هذه الاسهم + التداول وخبر يشكل انفجار
لو نظرت اخى الكريم فى مستوى حركته اليوميهقبل الخبر لا يتعدى 20 سنت فى ارتفاع ونزول ولكن الخبر الجيد + التداول الممتاز يجعل من حركته قويه وسريعه
نصيحتى لك لا تملك السهم اكثر من يوم واحد لكي تظمن حقك
من حيث التحليل ..اصبح السهم محصور ما بين 3.30 الديلى و4 الدولار
الديلى لا يقول به اندفاع كبير .. المقاومه الاتيه 3.61 والاقوى 3.93
والويكلى يشير الى السقوط الى 2.90
السهم ينتظر خبر جيد لكي يعاود الرتفاع مره اخرى وبقوة .. وفقك الله
دورة المؤشرنت للتحليل الفني
50 دينار كويتي